Bianchera, A.; Alomari, E.; Michielon, A.; Bazzoli, G.; Ronda, N.; Pighini, G.; Zanotti, I.; Giorgio, C.; Mozzarelli, A.; Bettini, R.;
et al. Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept. Pharmaceutics 2022, 14, 2754.
https://doi.org/10.3390/pharmaceutics14122754
AMA Style
Bianchera A, Alomari E, Michielon A, Bazzoli G, Ronda N, Pighini G, Zanotti I, Giorgio C, Mozzarelli A, Bettini R,
et al. Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept. Pharmaceutics. 2022; 14(12):2754.
https://doi.org/10.3390/pharmaceutics14122754
Chicago/Turabian Style
Bianchera, Annalisa, Esraa’a Alomari, Annalisa Michielon, Gianluca Bazzoli, Nicoletta Ronda, Giovanni Pighini, Ilaria Zanotti, Carmine Giorgio, Andrea Mozzarelli, Ruggero Bettini,
and et al. 2022. "Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept" Pharmaceutics 14, no. 12: 2754.
https://doi.org/10.3390/pharmaceutics14122754
APA Style
Bianchera, A., Alomari, E., Michielon, A., Bazzoli, G., Ronda, N., Pighini, G., Zanotti, I., Giorgio, C., Mozzarelli, A., Bettini, R., & Bruno, S.
(2022). Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept. Pharmaceutics, 14(12), 2754.
https://doi.org/10.3390/pharmaceutics14122754